Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meet...
02 Diciembre 2019 - 6:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host
a webcast and conference call on Tuesday, December 10, 2019 at 6:00
a.m. EST to review highlights from its presentations at the 61st
American Society of Hematology (ASH) Annual Meeting &
Exposition in Orlando, Florida, on December 7-10, 2019.
Guest Presenters:
- Rami Komrokji, M.D., Senior Member & Professor of Oncologic
Sciences, Section Head- Leukemia and MDS, Vice Chair-Malignant
Hematology Department, Moffitt Cancer Center, Tampa, Florida
- Thomas Coates, M.D., Professor of Pediatrics and Pathology,
Division of Hematology / Oncology, Children’s Hospital Los Angeles,
University of Southern California
- Srdan Verstovsek, M.D., Ph.D., Professor, Department of
Leukemia, The University of Texas MD Anderson Cancer Center,
Houston, Texas
The webcast will be accessible under "Events &
Presentations" in the Investors & Media page of the company's
website at www.acceleronpharma.com. Individuals can participate in
the conference call by dialing 877-312-5848 (domestic) or
253-237-1155 (international) and refer to the “Acceleron ASH 2019
Conference Call.”
The archived webcast will be available for replay on the
Acceleron website approximately two hours after the event.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. The Company's leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Bristol-Myers
Squibb, are co-promoting newly approved REBLOZYL®
(luspatercept-aamt), the first and only approved erythroid
maturation agent, in the United States and are developing
luspatercept for the treatment of chronic anemia in myelodysplastic
syndromes and myelofibrosis. Acceleron is also advancing its
neuromuscular program with ACE-083, a locally-acting Myostatin+
agent in Phase 2 development in Charcot-Marie-Tooth disease and is
conducting a Phase 2 pulmonary program with sotatercept in
pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191202005177/en/
Acceleron Pharma Inc. Investors: Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications Ed
Joyce, 617-649-9242 Director, Investor Relations Media: Matt
Fearer, 617-301-9557 Director, Corporate Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024